ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer

Reuters

2025/12/16

ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer

ImmunityBio, Inc. announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin $(BCG)$ shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.K., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2591803539"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591803539\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591803539?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591803539","market":"nz","top_or_hot":-1,"title":"ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin <a href=\"https://laohu8.com/S/BCG\">$(BCG)$</a> shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-16 22:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin <a href=\"https://laohu8.com/S/BCG\">$(BCG)$</a> shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL6Qm9P:1","article_id":"2591803539","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591803539","pubTimestamp":1765893704,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunityBio, Inc. announced new clinical study results demonstrating that treatment with ANKTIVA  in combination with Bacillus Calmette-Guérin  shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer . The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.K., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio报告ANKTIVA加BCG治疗BCG无反应膀胱癌的三年生存率为96%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n    \n\nImmunityBio, Inc. announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin $(BCG)$ shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.K., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}